Francis Wheeler

Cooley advised Work-Bench, a venture capital firm investing in early-stage enterprise software startups, on the close of its $160 million fourth fund.

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its $300 million incremental term loan and revolving credit commitments under its credit agreement with Ares Capital Corporation. Partners Addison Pierce and Michael Tollini led the Cooley team advising Tempus, which also included partner Eileen Marshall and associates JJ Meng, Stevie Yu and Yichao Zhang.

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.